Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron

Dow Jones Futures Jump As Putin Sees 'Positive Shift' In Ukraine Talks; Rivian, DocuSign Dive

Futures jumped early Friday as Putin cited positive shifts in Russia-Ukraine talks. The market rally showed resilience Thursday.

Investors Business Daily

IBD 50 Stocks To Watch: This Pharma Stock Is Building A New Base

IBD 50 Stocks To Watch: This Pharma Stock Is Building A New Base

Regeneron Pharmaceuticals rejoins the IBD 50 hot stocks to watch as it builds a new base and could break out.

Investors Business Daily

Buy the Dip in 3 Top-Rated Large-Cap Stocks

Buy the Dip in 3 Top-Rated Large-Cap Stocks

The increasing economic sanctions on Russia and consequent surge in oil prices and supply-chain disruptions will surely keep the stock market under pressure. Therefore, we think it could be wise to buy the price dip in quality large-cap stocks Regeneron Pharmaceuticals (REGN), Telefonaktiebolaget LM Ericsson (ERIC), and PPG Industries (PPG)…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC

BioNTech SE (NASDAQ:BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in advanced non-small-cell lung cancer (NSCLC). Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate the combination in different patient populations with advanced NSCLC and share…

Dow Jones Futures Pare 'Swift' Market Losses; West Targets Russia Banks Amid Ukraine Invasion

Dow Jones futures signal a market rally reversal as the West ramps up sanctions vs. Russia banks amid the ongoing Ukraine invasion.

Investors Business Daily

Kodiak Stock Pummeled After Attempt To Improve On Regeneron's Blockbuster Backfired

Kodiak Sciences' attempt to improve on Regeneron's blockbuster eye drug backfired on Wednesday — and investors pummeled KOD stock.

Investors Business Daily

The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings

Here's a roundup of top developments in the biotech space over the last 24 hours.

inkl

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Futures Erase Losses On Russia Comments; Market Rally At Key Level

Dow Jones Futures Erase Losses On Russia Comments; Market Rally At Key Level

Futures rose with Russia/Ukraine tensions in focus after the stock market rally sold off Friday. Tesla China sales were strong.

Investors Business Daily

Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis

Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis

Regeneron Scores Quarterly Beat — But How Long Will Its Covid Tailwind Persist?

Regeneron Scores Quarterly Beat — But How Long Will Its Covid Tailwind Persist?

Regeneron snagged a quarterly beat Friday, reporting sales growth almost entirely attributed to its Covid cocktail — and REGN stock rose.

Investors Business Daily

Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales

Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned

Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use

Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have

IBD 50 Stocks To Watch: Biotech Leader Regeneron Eyes New Buy Point In Volatile Market

IBD 50 Stocks To Watch: Biotech Leader Regeneron Eyes New Buy Point In Volatile Market

Among the top stocks to watch, top biotech stock Regeneron Pharmaceutical shows a new buy point in the current market weakness.

Investors Business Daily

FDA limits use of Regeneron and Lilly COVID antibody treatments

FDA limits use of Regeneron and Lilly COVID antibody treatments

The FDA said "data show these treatments are highly unlikely to be active" against Omicron.

Get all your
news in one place.

100’s of premium titles.
One news app.

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their emergency use authorization has been rescin

Tribune News Service

FDA halts use of 2 treatments found to be ineffective against omicron

WASHINGTON — U.S. regulators restricted the use of a pair of COVID-19 monoclonal antibody therapies after scientific evidence suggested they are unlikely to be effective against the omicron variant.

The Independent UK

FDA halts use of antibody drugs that don't work vs. omicron

U.S. health officials say COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don't work against the omicron variant

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

257,907 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play